Biomarin Pharmaceutical (BMRN) Acquisitions (2009 - 2016)
Biomarin Pharmaceutical's (BMRN) quarterly Acquisitions came in at $1.3 million in Q4 2016, down 99.75% on a QoQ basis from $538.4 million in Q1 2015.
Biomarin Pharmaceutical (BMRN) Acquisitions (2009 - 2016) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 5 years of Acquisitions data on file, last reported at $1.3 million in Q4 2016.
- Quarterly Acquisitions changed N/A year-over-year to $1.3 million in Q4 2016, while the trailing twelve-month figure through Dec 2017 was $1.3 million (changed 0.0% YoY) and the FY2016 annual result came in at $2.8 million, down 99.48% from the prior year.
- Acquisitions declined to $1.3 million in Q4 2016, from $538.4 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $538.4 million in Q1 2015 to a low of $1.3 million in Q4 2016.
- A 3-year average of $183.2 million and a median of $9.9 million in 2013 frame the typical range for Acquisitions.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 1.32 Mn |
| Mar 31, 2015 | 538.39 Mn |
| Mar 31, 2013 | 9.88 Mn |
| Sep 30, 2010 | 18.83 Mn |
| Mar 31, 2010 | 14.12 Mn |
| Dec 31, 2009 | 17.52 Mn |